The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...